financetom
Business
financetom
/
Business
/
US files complaint against fintech app Dave and its CEO
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
US files complaint against fintech app Dave and its CEO
Dec 31, 2024 4:23 AM

WASHINGTON (Reuters) -The U.S. Justice Department filed a complaint and announced a civil enforcement action on Monday against financial technology company Dave and its CEO Jason Wilk for alleged violations of federal law.

The Justice Department and the Federal Trade Commission alleged the company lured users to its personal finance app by advertising cash advances of up to $500 that many never receive.

The complaint, filed by the Justice Department, seeks unspecified amounts of consumer redress and monetary civil penalties from the defendants and a permanent injunction to prohibit them from engaging in future violations, the Justice Department said.

The government alleges that Dave misled consumers by deceptively advertising its cash advances, charging hidden fees, misrepresenting how Dave uses customers' tips and charging recurring monthly fees without providing a simple mechanism to cancel them.

Dave says many of the claims are incorrect and it will defend itself. It is also rolling out a streamlined fee structure that was unveiled earlier to remove tips and "express fees", which regulators allege it charged customers to get cash advances instantly.

New customers onboarded on or after Dec. 4 have been transitioned to this revised fee structure, Dave said on Tuesday, adding that existing customers are also shifting.

The complaint filed on Monday amends and replaces an earlier complaint that the FTC filed in November, which had named only Dave as a defendant and did not seek any civil penalties.

(Reporting by Kanishka Singh in Washington and Niket Nishant in Bengaluru; Editing by Chris Reese, Aurora Ellis and Devika Syamnath)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Blackstone considers selling visa firm VFS Global, Bloomberg News reports
Blackstone considers selling visa firm VFS Global, Bloomberg News reports
Sep 13, 2024
(Reuters) -Blackstone is considering options including a sale of its majority stake in visa application outsourcing and technology services firm VFS Global after receiving interest from prospective investors, Bloomberg News reported on Thursday. A potential transaction could value VFS at about $7 billion, Bloomberg reported, citing people familiar with the matter. Blackstone and VFS did not immediately respond to Reuters'...
TIMELINE-Boeing strike the latest challenge for troubled planemaker
TIMELINE-Boeing strike the latest challenge for troubled planemaker
Sep 13, 2024
(Updates with strike action) Sept 12 (Reuters) - Boeing's ( BA ) U.S. West Coast factory workers will walk off the job after 96% voted on Thursday in favor of a strike, halting production of the planemaker's strongest-selling jet as it wrestles with chronic output delays and mounting debt. Here is a timeline of issues surrounding Boeing ( BA ):...
Boeing strike the latest challenge for troubled planemaker
Boeing strike the latest challenge for troubled planemaker
Sep 13, 2024
(Reuters) -Boeing's U.S. West Coast factory workers will walk off the job after 96% voted on Thursday in favor of a strike, halting production of the planemaker's strongest-selling jet as it wrestles with chronic output delays and mounting debt. Here is a timeline of issues surrounding Boeing: OCTOBER 2018: A Lion Air MAX plane crashes in Indonesia, killing all 189...
Eli Lilly Gets US FDA Approval for Atopic Dermatitis Treatment
Eli Lilly Gets US FDA Approval for Atopic Dermatitis Treatment
Sep 13, 2024
04:46 PM EDT, 09/13/2024 (MT Newswires) -- Eli Lilly ( LLY ) said late Friday that the US Food and Drug Administration has approved Ebglyss, or lebrikizumab-lbkz, for the treatment of moderate-to-severe atopic dermatitis that is not well-controlled with topical prescription medicines in individuals aged 12 years and older who weigh at least 88 pounds. The approval is based on...
Copyright 2023-2025 - www.financetom.com All Rights Reserved